Preventing phosphorylation of dystroglycan ameliorates the dystrophic phenotype in mdx mouse.

Loss of dystrophin protein due to mutations in the DMD gene causes Duchenne muscular dystrophy. Dystrophin loss also leads to the loss of the dystrophin glycoprotein complex (DGC) from the sarcolemma which contributes to the dystrophic phenotype. Tyrosine phosphorylation of dystroglycan has been identified as a possible signal to promote the proteasomal degradation of the DGC. In order to test the role of tyrosine phosphorylation of dystroglycan in the aetiology of DMD, we generated a knock-in mouse with a phenylalanine substitution at a key tyrosine phosphorylation site in dystroglycan, Y890. Dystroglycan knock-in mice (Dag1(Y890F/Y890F)) had no overt phenotype. In order to examine the consequence of blocking dystroglycan phosphorylation on the aetiology of dystrophin-deficient muscular dystrophy, the Y890F mice were crossed with mdx mice an established model of muscular dystrophy. Dag1(Y890F/Y890F)/mdx mice showed a significant improvement in several parameters of muscle pathophysiology associated with muscular dystrophy, including a reduction in centrally nucleated fibres, less Evans blue dye infiltration and lower serum creatine kinase levels. With the exception of dystrophin, other DGC components were restored to the sarcolemma including α-sarcoglycan, α-/β-dystroglycan and sarcospan. Furthermore, Dag1(Y890F/Y890F)/mdx showed a significant resistance to muscle damage and force loss following repeated eccentric contractions when compared with mdx mice. While the Y890F substitution may prevent dystroglycan from proteasomal degradation, an increase in sarcolemmal plectin appeared to confer protection on Dag1(Y890F/Y890F)/mdx mouse muscle. This new model confirms dystroglycan phosphorylation as an important pathway in the aetiology of DMD and provides novel targets for therapeutic intervention.

[1]  J. Chamberlain,et al.  Expression of the dystrophin isoform Dp116 preserves functional muscle mass and extends lifespan without preventing dystrophy in severely dystrophic mice. , 2011, Human molecular genetics.

[2]  S. Winder,et al.  The proteasomal inhibitor MG132 prevents muscular dystrophy in zebrafish , 2011, PLoS currents.

[3]  K. Davies,et al.  Daily Treatment with SMTC1100, a Novel Small Molecule Utrophin Upregulator, Dramatically Reduces the Dystrophic Symptoms in the mdx Mouse , 2011, PloS one.

[4]  K. Davies,et al.  Current status of pharmaceutical and genetic therapeutic approaches to treat DMD. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[5]  K. Davies,et al.  Therapeutic approaches to muscular dystrophy. , 2011, Human molecular genetics.

[6]  P. Korkusuz,et al.  Mutation in exon 1f of PLEC, leading to disruption of plectin isoform 1f, causes autosomal-recessive limb-girdle muscular dystrophy. , 2010, American journal of human genetics.

[7]  M. Cilli,et al.  Therapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophies. , 2010, The American journal of pathology.

[8]  S. Winder,et al.  Dystroglycan versatility in cell adhesion: a tale of multiple motifs , 2010, Cell Communication and Signaling.

[9]  S. Winder,et al.  Modulation of cell spreading and cell-substrate adhesion dynamics by dystroglycan , 2010, Journal of Cell Science.

[10]  S. Winder,et al.  Dystroglycan, Tks5 and Src Mediated Assembly of Podosomes in Myoblasts , 2008, PloS one.

[11]  I. Graham,et al.  Codon and mRNA sequence optimization of microdystrophin transgenes improves expression and physiological outcome in dystrophic mdx mice following AAV2/8 gene transfer. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  W. Kunz,et al.  Myofiber integrity depends on desmin network targeting to Z-disks and costameres via distinct plectin isoforms , 2008, The Journal of cell biology.

[13]  F. Sotgia,et al.  Localized Treatment with a Novel FDA-Approved Proteasome Inhibitor Blocks the Degradation of Dystrophin and Dystrophin-Associated Proteins in mdx Mice , 2007, Cell cycle.

[14]  A. Ohtoshi,et al.  Nursing Essential for Proper Postnatal Growth and , Is Bsx A Brain-Specific Homeobox Gene , 2007 .

[15]  K. Davies,et al.  Plectin 1f scaffolding at the sarcolemma of dystrophic (mdx) muscle fibers through multiple interactions with β-dystroglycan , 2007, The Journal of cell biology.

[16]  J. Heighway,et al.  Over-expression of Microspan, a novel component of the sarcoplasmic reticulum, causes severe muscle pathology with triad abnormalities , 2006, Journal of Muscle Research & Cell Motility.

[17]  S. Winder,et al.  Sparks, signals and shock absorbers: how dystrophin loss causes muscular dystrophy. , 2006, Trends in cell biology.

[18]  F. Zara,et al.  Pharmacological rescue of the dystrophin-glycoprotein complex in Duchenne and Becker skeletal muscle explants by proteasome inhibitor treatment. , 2006, American journal of physiology. Cell physiology.

[19]  E. Le Rumeur,et al.  β‐Dystroglycan can be revealed in microsomes from mdx mouse muscle by detergent treatment , 2004, FEBS letters.

[20]  Yi Zhang,et al.  A map of WW domain family interactions , 2004, Proteomics.

[21]  K. Hoyte,et al.  Transgenic overexpression of dystroglycan does not inhibit muscular dystrophy in mdx mice. , 2004, The American journal of pathology.

[22]  David S. Park,et al.  Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins. , 2003, The American journal of pathology.

[23]  M. Wilson,et al.  Localization of phospho-beta-dystroglycan (pY892) to an intracellular vesicular compartment in cultured cells and skeletal muscle fibers in vivo. , 2003, Biochemistry.

[24]  J. Ervasti.  Costameres: the Achilles' Heel of Herculean Muscle* 210 , 2003, The Journal of Biological Chemistry.

[25]  P. Schmieder,et al.  WW domain sequence activity relationships identified using ligand recognition propensities of 42 WW domains , 2003, Protein science : a publication of the Protein Society.

[26]  F. Sotgia,et al.  Tyrosine phosphorylation of beta-dystroglycan at its WW domain binding motif, PPxY, recruits SH2 domain containing proteins. , 2001, Biochemistry.

[27]  S J Winder,et al.  The interaction of dystrophin with beta-dystroglycan is regulated by tyrosine phosphorylation. , 2001, Cellular signalling.

[28]  G. Morris,et al.  Epitopes in the interacting regions of beta-dystroglycan (PPxY motif) and dystrophin (WW domain). , 2001, Biochimica et biophysica acta.

[29]  S J Winder,et al.  The complexities of dystroglycan. , 2001, Trends in biochemical sciences.

[30]  S. Winder,et al.  Adhesion-dependent tyrosine phosphorylation of (beta)-dystroglycan regulates its interaction with utrophin. , 2000, Journal of cell science.

[31]  H. Lassmann,et al.  Targeted inactivation of plectin reveals essential function in maintaining the integrity of skin, muscle, and heart cytoarchitecture. , 1997, Genes & development.

[32]  I. Blumcke,et al.  Altered distribution of plectin/HD1 in dystrophinopathies , 1997, Neuromuscular Disorders.

[33]  J. Sanes,et al.  Skeletal and Cardiac Myopathies in Mice Lacking Utrophin and Dystrophin: A Model for Duchenne Muscular Dystrophy , 1997, Cell.

[34]  Susan C. Brown,et al.  Utrophin-Dystrophin-Deficient Mice as a Model for Duchenne Muscular Dystrophy , 1997, Cell.

[35]  K. Davies,et al.  Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene , 1996, Nature.

[36]  H. Shimizu,et al.  Homozygous deletion mutations in the plectin gene (PLEC1) in patients with epidermolysis bullosa simplex associated with late-onset muscular dystrophy. , 1996, Human molecular genetics.

[37]  E. Lane,et al.  Plectin deficiency results in muscular dystrophy with epidermolysis bullosa , 1996, Nature Genetics.

[38]  K. Campbell,et al.  Exogenous Dp71 restores the levels of dystrophin associated proteins but does not alleviate muscle damage in mdx mice , 1994, Nature Genetics.

[39]  K. Campbell,et al.  Dp71 can restore the dystrophin-associated glycoprotein complex in muscle but fails to prevent dystrophy , 1994, Nature Genetics.

[40]  M. Noble,et al.  Myogenic cell lines derived from transgenic mice carrying a thermolabile T antigen: a model system for the derivation of tissue-specific and mutation-specific cell lines. , 1994, Developmental biology.

[41]  J. Ervasti,et al.  A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin , 1993, The Journal of cell biology.

[42]  K. Davies,et al.  Localization and Quantitation of the Chromosome 6-Encoded Dystrophin-Related Protein in Normal and Pathological Human Muscle , 1993, Journal of neuropathology and experimental neurology.

[43]  J. Ervasti,et al.  Association of dystrophin-related protein with dystrophin-associated proteins in mdx mouse muscle , 1992, Nature.

[44]  K. Davies,et al.  Localization of the DMDL gene-encoded dystrophin-related protein using a panel of nineteen monoclonal antibodies: presence at neuromuscular junctions, in the sarcolemma of dystrophic skeletal muscle, in vascular and other smooth muscles, and in proliferating brain cell lines , 1991, The Journal of cell biology.

[45]  D. Andrews,et al.  A nascent membrane protein is located adjacent to ER membrane proteins throughout its integration and translation , 1991, The Journal of cell biology.

[46]  J. Ervasti,et al.  Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle , 1990, Nature.

[47]  H. Bye-A-Jee,et al.  Physiological characterization of muscle strength with variable levels of dystrophin restoration in mdx mice following local antisense therapy. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[48]  K. Davies,et al.  Dystrophin-related protein, utrophin, in normal and dystrophic human fetal skeletal muscle , 2004, The Histochemical Journal.